Literature DB >> 12849668

Modulating effects of age and gender on the clinical course of long QT syndrome by genotype.

Wojciech Zareba1, Arthur J Moss, Emanuela H Locati, Michael H Lehmann, Derick R Peterson, W Jackson Hall, Peter J Schwartz, G Michael Vincent, Silvia G Priori, Jesaia Benhorin, Jeffrey A Towbin, Jennifer L Robinson, Mark L Andrews, Carlo Napolitano, Katherine Timothy, Li Zhang, Aharon Medina.   

Abstract

OBJECTIVES: We aimed to determine whether long QT syndrome (LQTS) genotype has a differential effect on clinical course of disease in male and female children and adults after adjustment for QTc duration.
BACKGROUND: Genotype influences clinical course of the LQTS; however, data on the effect of age and gender on this association are limited.
METHODS: The LQTS genotype, QTc duration, and follow-up were determined in 243 cases of LQTS caused by the KCNQ1 potassium channel gene mutations (LQT1), 209 cases of LQTS caused by the HERG potassium channel gene mutations (LQT2), and 81 cases of LQTS caused by the SCN5A sodium channel gene mutation (LQT3) gene carriers. The probability of cardiac events (syncope, aborted cardiac arrest, or sudden death) was analyzed by genotype, gender, and age (children < or = 15 years and adults 16 to 40 years). In addition, the risk of sudden death and lethality of cardiac events were evaluated in 1,075 LQT1, 976 LQT2, and 324 LQT3 family members from families with known genotype.
RESULTS: During childhood, the risk of cardiac events was significantly higher in LQT1 males than in LQT1 females (hazard ratio [HR] = 1.72), whereas there was no significant gender-related difference in the risk of cardiac events among LQT2 and LQT3 carriers. During adulthood, LQT2 females (HR = 3.71) and LQT1 females (HR = 3.35) had a significantly higher risk of cardiac events than respective males. The lethality of cardiac events was highest in LQT3 males and females (19% and 18%), and higher in LQT1 and LQT2 males (5% and 6%) than in LQT1 and LQT2 females (2% for both). CONCLUSIONS; Age and gender have different, genotype-specific modulating effects on the probability of cardiac events and electrocardiographic presentation in LQT1 and LQT2 patients.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12849668     DOI: 10.1016/s0735-1097(03)00554-0

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  70 in total

1.  Risk of recurrent cardiac events after onset of menopause in women with congenital long-QT syndrome types 1 and 2.

Authors:  Jonathan Buber; Jehu Mathew; Arthur J Moss; W Jackson Hall; Alon Barsheshet; Scott McNitt; Jennifer L Robinson; Wojciech Zareba; Michael J Ackerman; Elizabeth S Kaufman; David Luria; Michael Eldar; Jeffrey A Towbin; Michael Vincent; Ilan Goldenberg
Journal:  Circulation       Date:  2011-05-31       Impact factor: 29.690

2.  Risk of syncope in family members who are genotype-negative for a family-associated long-QT syndrome mutation.

Authors:  Alon Barsheshet; Arthur J Moss; Scott McNitt; Slava Polonsky; Coeli M Lopes; Wojciech Zareba; Jennifer L Robinson; Michael J Ackerman; Jesaia Benhorin; Elizabeth S Kaufman; Jeffrey A Towbin; G Michael Vincent; Ming Qi; Ilan Goldenberg
Journal:  Circ Cardiovasc Genet       Date:  2011-08-10

3.  Genotype- and mutation site-specific QT adaptation during exercise, recovery, and postural changes in children with long-QT syndrome.

Authors:  Peter F Aziz; Tammy S Wieand; Jamie Ganley; Jacqueline Henderson; Akash R Patel; V Ramesh Iyer; R Lee Vogel; Michael McBride; Victoria L Vetter; Maully J Shah
Journal:  Circ Arrhythm Electrophysiol       Date:  2011-09-28

Review 4.  Drug-induced long QT syndrome.

Authors:  Prince Kannankeril; Dan M Roden; Dawood Darbar
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

5.  Risk for life-threatening cardiac events in patients with genotype-confirmed long-QT syndrome and normal-range corrected QT intervals.

Authors:  Ilan Goldenberg; Samuel Horr; Arthur J Moss; Coeli M Lopes; Alon Barsheshet; Scott McNitt; Wojciech Zareba; Mark L Andrews; Jennifer L Robinson; Emanuela H Locati; Michael J Ackerman; Jesaia Benhorin; Elizabeth S Kaufman; Carlo Napolitano; Pyotr G Platonov; Silvia G Priori; Ming Qi; Peter J Schwartz; Wataru Shimizu; Jeffrey A Towbin; G Michael Vincent; Arthur A M Wilde; Li Zhang
Journal:  J Am Coll Cardiol       Date:  2011-01-04       Impact factor: 24.094

Review 6.  ECG repolarization waves: their genesis and clinical implications.

Authors:  Thinn Hlaing; Tara DiMino; Peter R Kowey; Gan-Xin Yan
Journal:  Ann Noninvasive Electrocardiol       Date:  2005-04       Impact factor: 1.468

7.  Clinical, genetic, and electrophysiologic characteristics of a new PAS-domain HERG mutation (M124R) causing Long QT syndrome.

Authors:  Liat Shushi; Batsheva Kerem; Maya Goldmit; Asher Peretz; Bernard Attali; Aron Medina; Jeffrey A Towbin; Junko Kurokawa; Robert S Kass; Jesaia Benhorin
Journal:  Ann Noninvasive Electrocardiol       Date:  2005-07       Impact factor: 1.468

8.  Measure of the QT-RR dynamic coupling in patients with the long QT syndrome.

Authors:  Josef Halamek; Jean-Philippe Couderc; Pavel Jurak; Vlastimil Vondra; Wojciech Zareba; Ivo Viscor; Pavel Leinveber
Journal:  Ann Noninvasive Electrocardiol       Date:  2012-08-13       Impact factor: 1.468

Review 9.  Sudden cardiac death without structural heart disease: update on the long QT and Brugada syndromes.

Authors:  Ilan Goldenberg; Arthur J Moss; Wojciech Zareba
Journal:  Curr Cardiol Rep       Date:  2005-09       Impact factor: 2.931

10.  Clinical aspects of type-1 long-QT syndrome by location, coding type, and biophysical function of mutations involving the KCNQ1 gene.

Authors:  Arthur J Moss; Wataru Shimizu; Arthur A M Wilde; Jeffrey A Towbin; Wojciech Zareba; Jennifer L Robinson; Ming Qi; G Michael Vincent; Michael J Ackerman; Elizabeth S Kaufman; Nynke Hofman; Rahul Seth; Shiro Kamakura; Yoshihiro Miyamoto; Ilan Goldenberg; Mark L Andrews; Scott McNitt
Journal:  Circulation       Date:  2007-04-30       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.